---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006202"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:14:10.231656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies

## Summary
- PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.
- PMN310 avoided binding to plaque and vascular deposits, potentially reducing ARIA-E and ARIA-H risks.
- Weekly murine PMN310 dosing at 800 mg/kg for 26 weeks in AD mice showed no detectable brain hemorrhages.
- Phase 1a study in healthy volunteers ongoing; initial safety/PK data expected mid-2024.

## SEC filing metadata
- accession: 0001558370-24-006202
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/0001558370-24-006202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/pmn-20240430x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006202
- JSON: https://secwatch.observer/filing/0001558370-24-006202.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.